Navigating from target identification to validation can be a complex and time consuming process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of costly clinical trials. CRISPR-Cas screens have made a substantial impact in this space, being seen as a robust route for target identification and validation. However, drugs that target the proteins encoded by the genes identified in the CRISPR-Cas screen can also aid rapid validation of a particular pathway involved in a biological process of interest (such as differentiation state or drug resistance).

This webinar explores how CRISPR-Cas screens combined with in vitro cell panel drug screens in the immune cell space can aid the validation process ahead of moving into pre-clinical and clinical trials.